[1. SENTÍM, ROMERO R, PEDRO-BOTET J, PELEGRÍA, NOGUÉS X, RUBIÉS-PRAT J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int. 1992; 41:1394.10.1038/ki.1992.204]Search in Google Scholar
[2. ATTMAN PO, SAMUELSSON O, ALAUPOVIC P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993; 21:573.10.1016/S0272-6386(12)80030-8]Search in Google Scholar
[3. ARNADOTTIR M, THYSELL H, DALLONGEVILLE J, FRUCHART JC, NILSSON-EHLE P. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int. 1995; 48:779.10.1038/ki.1995.350]Search in Google Scholar
[4. LACOUR B, ROULLET JB, LIAGRE AM, JORGETTI V, BEYNE P, DUBOST C, DRÜEKE T. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis. 1986; 8:422.10.1016/S0272-6386(86)80169-X]Search in Google Scholar
[5. LIANG K, OVEISI F, VAZIRI ND. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int. 1998; 53:626.10.1046/j.1523-1755.1998.00786.x]Search in Google Scholar
[6. AKMAL M, PERKINS S, KASIM SE, OH HY, SMOGORZEWSKI M, MASSRY SG. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am J Kidney Dis. 1993; 22:158.10.1016/S0272-6386(12)70182-8]Search in Google Scholar
[7. CHEUNG AK, PARKER CJ, REN K, IVERIUS PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int. 1996; 49:1360.10.1038/ki.1996.1928731101]Search in Google Scholar
[8. KRIS-ETHERTON PM, HARRIS WS, APPEL LJ, et al. American Heart Association, Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002; 106:2747-2757.10.1161/01.CIR.0000038493.65177.94]Search in Google Scholar
[9. SERHAN CN, HONG S, GRONERT K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med.2002;196: 1025-1037.10.1084/jem.20020760219403612391014]Search in Google Scholar
[10. HARRIS WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin. Nutr. 1997; 65:1645S-1654S.10.1093/ajcn/65.5.1645S9129504]Search in Google Scholar
[11. ERITSLAND J, ARNESEN H, GRONSETH K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol. 1996; 77:31-36.10.1016/S0002-9149(97)89130-8]Search in Google Scholar
[12. THIES F, GARRY JM, YAQOOB P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet. 2003; 361:477-485.10.1016/S0140-6736(03)12468-3]Search in Google Scholar
[13. FRIEDMAN AN, MOE SM, PERKINS SM, et al. Fish consumption and omega-3 fatty acid status and determinants in longterm hemodialysis. J Am Kidney Dis 2006:1064-1071.10.1053/j.ajkd.2006.03.03316731302]Search in Google Scholar
[14. FRIEDMAN AN, SIDDIQUI R, WATKINS BA. Acute rise of omega-3 polyunsaturated fatty acids during hemodialysis treatment. J Ren Nutr 2008; 18(3):301-3.10.1053/j.jrn.2007.11.002238695218410887]Search in Google Scholar
[15. OMRANI HR, PASDAR Y, RAISI D, NAJAFI F, ESFANDIARI A. The effect of omega-3 on serum lipid profile in hemodialysis patients. J Renal Inj Prev. 2015; 4:68-72.]Search in Google Scholar
[16. TAZIKI O, LESSAN-PEZESHKI M, AKHA O, VASHEGHANI F. The effect of low dose omega-3 on plasma lipids in hemodialysis patients. Saudi J Kidney Dis Transpl. 2007; 18(4):571-6.]Search in Google Scholar
[17. HASSAN KS, HASSAN SK, HIJAZI EG, KHAZIM KO. Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Ren Fail. 2010; 32:1031-5.10.3109/0886022X.2010.51023120863205]Search in Google Scholar
[18. BAYS HE, TIGHE AP, SADOVSKY R, DAVIDSON MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc. Ther. 2008; 6:391-409.]Search in Google Scholar
[19. HARRIS WS. N-3 Fatty acids and serum lipoproteins: human studies. Am J Clin. Nutr 1997; 65:S1645-54.10.1093/ajcn/65.5.1645S9129504]Search in Google Scholar
[20. LAPUZ M, AVRAM MM, LUSTIG A, GOLDWASSER P, ANTIGNANI A, FEIN PA, et al. Fall of cholesterol with time on dialysis: impact on atherogenicity. ASAIO Trans. 1989; 35:258-60.10.1097/00002216-198907000-00026]Search in Google Scholar
[21. CHI H, LIN X, HUANG H, ZHENG X, LI T, ZOU Y. Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: meta-analysis. Arch Med Res. 2014; 45:469-77.10.1016/j.arcmed.2014.06.00825010561]Search in Google Scholar
[22. ASHTIYANI SC, NAJAFI H, KABIRINIA K, VAHEDI E, JAMEBOZORKYL. Oral omega-3 fatty acid for reduction of kidney dysfunction induced by reperfusion injury in rats. Iran J Kidney Dis. 2012; 6:275-83.]Search in Google Scholar
[23. HOLM T, ANDREASSEN AK, AUKRUST P, ANDERSEN K, GEIRAN OR, KJEKSHUS J, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J. 2001; 22:428-36.10.1053/euhj.2000.236911207085]Search in Google Scholar